JOP20210312A1 - أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها - Google Patents

أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها

Info

Publication number
JOP20210312A1
JOP20210312A1 JOP/2021/0312A JOP20210312A JOP20210312A1 JO P20210312 A1 JOP20210312 A1 JO P20210312A1 JO P20210312 A JOP20210312 A JO P20210312A JO P20210312 A1 JOP20210312 A1 JO P20210312A1
Authority
JO
Jordan
Prior art keywords
methanesulfonylphenoxy
fluoro
propyl
amine
ethyl
Prior art date
Application number
JOP/2021/0312A
Other languages
Arabic (ar)
English (en)
Inventor
Joakim Mihkel Tedroff
Inese Reine
Clas Sonesson
Ross Nicholas Waters
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of JOP20210312A1 publication Critical patent/JOP20210312A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JOP/2021/0312A 2019-05-24 2021-11-24 أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها JOP20210312A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (1)

Publication Number Publication Date
JOP20210312A1 true JOP20210312A1 (ar) 2023-01-30

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0312A JOP20210312A1 (ar) 2019-05-24 2021-11-24 أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها

Country Status (21)

Country Link
US (2) US12275694B2 (enExample)
EP (2) EP3976581B1 (enExample)
JP (1) JP7623958B2 (enExample)
KR (1) KR102892833B1 (enExample)
CN (1) CN113853369B (enExample)
AU (1) AU2020286003B2 (enExample)
BR (1) BR112021023563A2 (enExample)
CA (1) CA3140805A1 (enExample)
CL (1) CL2021003115A1 (enExample)
CO (1) CO2021016556A2 (enExample)
DK (1) DK3976581T3 (enExample)
ES (2) ES2970361T3 (enExample)
FI (1) FI3976581T3 (enExample)
IL (1) IL288271B2 (enExample)
JO (1) JOP20210312A1 (enExample)
MX (1) MX2021014271A (enExample)
PH (1) PH12021552844A1 (enExample)
PL (1) PL3976581T3 (enExample)
PT (1) PT3976581T (enExample)
SG (1) SG11202112165QA (enExample)
WO (1) WO2020239568A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
JP7688690B2 (ja) 2020-07-28 2025-06-04 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
JP2023548429A (ja) * 2020-11-10 2023-11-16 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー パーキンソン病、特にl-dopa誘発性ジスキネジアのための医薬品に対する感作の予防または軽減における使用のための[2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミン(メスドペタム)
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
CA3268423A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts thereof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123821A (en) 1975-04-18 1976-10-28 Nippon Kayaku Co Ltd An algicide and protective agent
US4128574A (en) * 1976-10-04 1978-12-05 General Electric Company Method for making organic polycarboxylic acids
GB8823405D0 (en) 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
ES2169102T3 (es) 1994-10-14 2002-07-01 Merck Patent Gmbh (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano como agente activo sobre el sistema nervioso central.
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
JP2006193494A (ja) 2005-01-17 2006-07-27 Dainippon Ink & Chem Inc 4級アンモニウム系化合物を有効成分とする心臓疾患治療剤
CN101203511A (zh) 2005-06-23 2008-06-18 阿斯利康(瑞典)有限公司 作为神经激肽受体拮抗剂用于治疗胃肠疾病的新氮杂环丁烷衍生物
WO2007063789A1 (ja) 2005-11-29 2007-06-07 Kissei Pharmaceutical Co., Ltd. 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2007072041A1 (en) 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
AU2007218086A1 (en) * 2006-02-15 2007-08-30 M's Science Corporation Piperazine derivatives
CA2687721A1 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
JP2011519839A (ja) 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2009133110A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
MX2010011724A (es) 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
US9006227B2 (en) * 2011-04-19 2015-04-14 Integrative Research Laboratories Sweden Ab Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
MX391727B (es) 2016-02-08 2025-03-21 Merck Patent Gmbh Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-metilbenzoil)guanidina.
EP3625213B1 (en) 2017-05-19 2023-03-08 Integrative Research Laboratories Sweden AB (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof
SG11202000833YA (en) * 2017-08-07 2020-02-27 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
WO2020110128A1 (en) 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Also Published As

Publication number Publication date
WO2020239568A1 (en) 2020-12-03
JP7623958B2 (ja) 2025-01-29
EP3976581A1 (en) 2022-04-06
MX2021014271A (es) 2022-01-06
KR20220011638A (ko) 2022-01-28
BR112021023563A2 (pt) 2022-01-04
US20240343687A2 (en) 2024-10-17
EP4292653A3 (en) 2024-04-24
US20250243155A1 (en) 2025-07-31
EP4292653A2 (en) 2023-12-20
CO2021016556A2 (es) 2022-01-17
IL288271A (en) 2022-01-01
ES3072819T3 (en) 2026-07-06
PL3976581T3 (pl) 2024-07-01
AU2020286003B2 (en) 2025-04-24
KR102892833B1 (ko) 2025-12-02
CN113853369A (zh) 2021-12-28
EP3976581B1 (en) 2023-11-22
IL288271B2 (en) 2025-02-01
IL288271B1 (en) 2024-10-01
CN113853369B (zh) 2025-08-22
PH12021552844A1 (en) 2022-10-17
EP4292653B1 (en) 2026-03-18
US12275694B2 (en) 2025-04-15
CA3140805A1 (en) 2020-12-03
ES2970361T3 (es) 2024-05-28
DK3976581T3 (da) 2024-01-22
SG11202112165QA (en) 2021-12-30
JP2022533433A (ja) 2022-07-22
PT3976581T (pt) 2024-02-08
US20220267262A1 (en) 2022-08-25
AU2020286003A1 (en) 2021-12-02
CL2021003115A1 (es) 2022-09-30
FI3976581T3 (fi) 2024-01-31

Similar Documents

Publication Publication Date Title
PH12021552844A1 (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
ZA202104112B (en) 15-pgdh inhibitor
CR20220354A (es) Inhibidores de egfr
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
JOP20240290A1 (ar) أملاح أوبيسترابيب وعمليات تصنيعها والمركبات الوسيطة منها
EA202190756A1 (ru) Способ использования алканоламина при размоле
PH12022553498A1 (en) Novel acid secretion inhibitor and use thereof
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
PY2242414A (es) Intermedio novedoso para la preparación de piroxasulfona
EP4410773A3 (en) Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
MX2023000970A (es) Metodo de preparacion de aminofuranos.
JOP20230087A1 (ar) ناهض مستقبلات الميلانوكورتين-4 غير المتبلور
EP4410989A3 (en) Method for producing heterocyclidene acetamide derivatives
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.
CR20240173A (es) Compuestos de cd73
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
CL2024003173A1 (es) Compuestos de administración de gamma-hidroxibutirato y procesos para elaboración y uso de los mismos
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
AR126196A1 (es) Proceso para preparar inhibidores de egfr
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
PH12021551957A1 (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative